Latanoprost / Timolol Fdc International

Timolol maleate and Latanoprost, the active ingredients in Latanoprost / Timolol Fdc International, are a beta‑blocker and prostaglandin analog presented as an ophthalmic solution for ocular use. They are employed to lower intra‑ocular pressure in patients with glaucoma or ocular hypertension. GNH USA supplies Latanoprost / Timolol Fdc International as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol is indicated for conditions that require reduction of intra‑ocular pressure within the glaucoma disease family.

Open‑angle glaucoma: lowers eye pressure to slow optic nerve damage. Ocular hypertension: reduces pressure to prevent progression to glaucoma. Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision shortly after instillation - Conjunctival hyperemia (redness) - Foreign body sensation - Increased eyelash length or thickness - Darkening of the iris or peri‑ocular skin

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Paradoxical increase in intra‑ocular pressure - Corneal edema or keratitis - Anterior uveitis or iritis - Systemic beta‑blocker effects such as bradycardia or bronchospasm - Persistent eye pain or vision loss

Before using Latanoprost/Timolol, consider the following precautions.

Cardiovascular assessment: evaluate for bradycardia or heart block. Respiratory status: avoid in patients with severe asthma or COPD. Sulfonamide allergy: timolol contains a sulfonamide moiety; assess hypersensitivity. Ocular pigmentation: monitor for iris or peri‑ocular skin darkening. Pregnancy and lactation: use only if benefits outweigh potential risks. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost/Timolol may interact with other medicines; review the following.

Major Interactions (Avoid): - Concurrent systemic beta‑blockers: risk of additive bradycardia. - Other ocular hypotensive agents: may cause excessive pressure lowering. - Sympathomimetic eye drops: can reduce timolol efficacy. - Sulfonamide antibiotics: increased risk of hypersensitivity reactions. - Multiple prostaglandin analogs: heightened ocular inflammation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise timolol plasma levels. - Anticholinergic eye drops: possible reduction in pressure‑lowering effect. - Topical NSAIDs: may increase ocular irritation. - Systemic antihistamines: can exacerbate dry eye symptoms. - Other beta‑blocker eye drops: monitor for cumulative cardiovascular effects.